Phase 1 Leukaemia Trial, Recruiting NCT07250087 Sponsor: H. Lee Moffitt Cancer Center and Research Institute Condition: Leukaemia
Back to Leukaemia

Phase 1 Leukaemia Trial, Recruiting

NCT07250087
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who have been diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL), where certain genetic abnormalities can still be detected
  • People whose leukemia is currently in remission, meaning fewer than 5% of abnormal cells (blasts) are found in the bone marrow
  • People who are in reasonably good general health and able to carry out daily activities (confirm with trial site for exact fitness level required)
  • People whose major organs such as the liver, kidneys, and heart are functioning well enough to meet the trial's requirements

Who may not be able to join:

  • People whose leukemia has come back and is active, with more than 5% abnormal cells (blasts) present in the bone marrow
  • People who have developed a moderate to severe immune reaction called graft-versus-host disease (GVHD) after a transplant, which is currently being treated with steroid medications
  • People who have serious problems with how their major organs are working, or who have an infection that is not currently under control
  • People who are pregnant or currently breastfeeding
  • People who have previously received an experimental CAR T-cell therapy as part of another clinical trial or investigational treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Rawan Faramand, MD, Moffitt Cancer Center

Phone: 813-745-3178

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
21 January 2026
Est. completion
1 November 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recommended Phase 2 Dose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov